Considerations & Opportunities in Capturing Oncology Patients’ PRO Data Date Published: Mar 06, 2023 Webinar On February 28, Signant’s Bill Byrom, PhD, sat down with TransPerfect to discuss the impact of recent FDA draft guidance on instrument selection and measurement strategies for capturing patient-reported outcome (PRO) data in modern oncology trials. The panelists also shared key considerations for trial designs that reduce patient burdens, examined the potential of item banks and augmentation of current tools, and explained the need for specificity of instruments to support labeling claims. To tune into more oncology and eCOA expert insights, tune into the webinar recording below. Share: LinkedInTweet Recommended Resources COA Measurement Strategy in Modern Oncology Trials Watch Now Webinar The Impact of FDA Draft Guidance for Oncology Patient-Reported Outcomes Download Now Whitepaper Video Oncology Complete Solution Overview Oncology research today is more multifaceted and nuanced than ever. Sponsors and CROs need flexible, appropriate technology solutions and oncology-specific scientific... Watch Now